Tarek Mouhieddine, MD

Dr. Tarek Mouhieddine is a physician–scientist and clinical investigator whose research focuses on understanding mechanisms of resistance to myeloma therapies, including CAR T cell therapy and bispecific antibodies, and developing novel therapeutic strategies to improve patient outcomes. He has a strong background in lab-based and translational research, with expertise in tumor genomics and the immune microenvironment. Dr. Mouhieddine is passionate about advancing precision cancer care, the early detection and interception of blood cancers, and translating laboratory discoveries into first-in-human phase I clinical trials in multiple myeloma.